Genome-wide Association Study Identifies a Regulatory Variant of RGMA Associated With Opioid Dependence in European Americans.
- Authors
- Cheng, Zhongshan; Zhou, Hang; Sherva, Richard; Farrer, Lindsay A; Kranzler, Henry R; Gelernter, Joel
- Year
- 2018
- Journal
- Biological psychiatry
- PMID
- 29478698
- DOI
- 10.1016/j.biopsych.2017.12.016
- PMCID
- PMC6041180
BACKGROUND: Opioid dependence (OD) is at epidemic levels in the United States. Genetic studies can provide insight into its biology. METHODS: We completed an OD genome-wide association study in 3058 opioid-exposed European Americans, 1290 of whom met criteria for a DSM-IV diagnosis of OD. Analysis used DSM-IV criterion count. RESULTS: By meta-analysis of four cohorts, Yale-Penn 1 (n = 1388), Yale-Penn 2 (n = 996), Yale-Penn 3 (n = 98), and SAGE (Study of Addiction: Genetics and Environment) (n = 576), we identified a variant on chromosome 15, rs12442183, near RGMA, associated with OD (p = 1.3 × 10). The association was also genome-wide significant in Yale-Penn 1 taken individually and nominally significant in two of the other three samples. The finding was further supported in a meta-analysis of all available opioid-exposed African Americans (n = 2014 [1106 meeting DSM-IV OD criteria]; p = 3.0 × 10) from three cohorts; there was nominal significance in two of these samples. Thus, of seven subsamples examined in two populations, one was genome-wide significant, and four of six were nominally (or nearly) significant. RGMA encodes repulsive guidance molecule A, which is a central nervous system axon guidance protein. Risk allele rs12442183*T was correlated with higher expression of a specific RGMA transcript variant in frontal cortex (p = 2 × 10). After chronic morphine injection, the homologous mouse gene (Rgma) was upregulated in C57BL/6J striatum. Coexpression analysis of 1301 brain samples revealed that RGMA messenger RNA expression was associated with that of four genes implicated in other psychiatric disorders, including GRIN1. CONCLUSIONS: This is the first study to demonstrate an association of RGMA with OD. It provides a new lead into our understanding of OD pathophysiology.
Manhattan plots showing genome-wide association signals of opioid dependence in opioid-exposed European-Americans by meta-analysis(A) Manhattan plot with one significant variant, rs12442183, on chromosome 15, in meta-analysis of four OD cohorts. The line in the plot represents the genome-wide significance cutoff (5×10-8). (B) Regional Manhattan plot demonstrates rs12442183 is close to gene RGMA (and regulates RGMA expression; see Figure 3 and text). The light blue line and right Y-axis show the observed recombination rate in the 1000 Genomes Project European samples (EUR, hg19). The SNPs are colored in accordance to R2 with rs12442183 (in purple), except for rs113200177, which is specifically highlighted in dark. rs113200177 (T/TG, meta-P=2×10-3) is located in the promoter of RGMA and is predicted to be able to destroy the E-box motif (5′-CANNTG-3′) of transcription factor 3 or 4 (TCF3 or TCF4) by Haploreg4 (45). By adjusting the effect of the indel in conditional association analysis for rs12442183, the association signal of rs12442183 became stronger in Yale-Penn 1 taken individually (P=1.9×10-8).
Forest plot for rs12442183 risk allele T in opioid dependence GWASEffect Beta and its 95% confidence interval are plotted with squares (proportional to sample size in each cohort) and horizontal lines with whiskers, respectively. The vertical line (beta=0) indicates no effect. Names of cohorts are shown on the left. Meta-analysis P-values and their corresponding effect betas (red diamonds) for European-American (EA) and African-American (AA) populations are also provided. The forest plot was generated by DistillerSR Forest Plot Generator from Evidence Partners (https://www.evidencepartners.com/resources/forest-plot-generator).
rs12442183 is a regulatory variant of RGMA and Rgma is an acute opioid response gene in mouse(A) Six transcripts of RGMA and four exons used for alternative splicing analysis are mapped together. The relationship between the expression of these four exons and RGMA gene expression was determined by using a linear regression model implemented in R package ESLiMc. The difference between the observed exon expression and the predicted exon expression is named as residual regression score. The alternative splicing events of RGMA across 11 healthy human tissues are displayed in (B), with dot and error-bar represent mean and standard deviation of 3 replicates, respectively. Boxplots (C) are used to illustrate the association between rs12442183 genotype and the residual regression scores of four exons in brain tissue frontal cortex in European samples. Dot and line within each boxplot represent mean and median, respectively, and box region indicates the range from first quantile to third quantile. Up and down whiskers, as well as dots outside box region represent maximum value, minimum value, and outliers, respectively. (D) The expression of Rgma (homologous gene in mouse) among different mouse strains acutely after morphine injection (a single injection, 20 mg/kg) in comparison with chronic injections (repeated morphine administration, 10-40 mg/kg, 3 times daily for 5 days). X-axis shows the four inbred mouse strains (129P3/J, DBA/2J, C57BL/6J and SWR/J). Y-axis demonstrates the mRNA expression of mouse gene Rgma. The expression data were derived from NCBI Gene Expression Omnibus (GEO) dataset GSE7762. The standard deviation is at the top of each bar.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Addiction Susceptibility: Genetic Factors, Personality Traits, and Epigenetic Interactions with the Gut Microbiome. | Borrego-Ruiz A et al. | — | 2025 | → |
| Genome-wide association study reveals multiple loci for nociception and opioid consumption behaviors associated with heroin vulnerability in outbred rats. | Kuhn BN et al. | — | 2025 | → |
| Scoping review of associations between cytochrome P450 3A4/5 single nucleotide polymorphisms and risk factors for fentanyl overdose. | Petrovitch D et al. | — | 2025 | → |
| Whole-exome sequencing study of opioid dependence offers novel insights into the contributions of exome variants. | Wang L et al. | — | 2025 | → |
| A genome-wide Association study of the Count of Codeine prescriptions. | Song W et al. | — | 2024 | → |
| Genetic Variants Linked to Opioid Addiction: A Genome-Wide Association Study. | Panday SK et al. | — | 2024 | → |
| Novel KCNQ2 missense variant expands the genotype spectrum of DEE7. | Wang C et al. | — | 2024 | → |
| Opioid trail: Tracking contributions to opioid use disorder from host genetics to the gut microbiome. | Duffy EP et al. | — | 2024 | → |
| Sex and genetic background influence intravenous oxycodone self-administration in the hybrid rat diversity panel. | Duffy EP et al. | — | 2024 | → |
| The genetic landscape of substance use disorders. | Gerring ZF et al. | — | 2024 | → |
| Genome-wide analyses reveal novel opioid use disorder loci and genetic overlap with schizophrenia, bipolar disorder, and major depression. | Holen B et al. | — | 2023 | → |
| Specificity in genetic and environmental risk for prescription opioid misuse and heroin use. | Dash GF et al. | — | 2023 | → |
| The Opioid Epidemic: a Crisis Disproportionately Impacting Black Americans and Urban Communities. | Gondré-Lewis MC et al. | — | 2023 | → |
| Analyses of polymorphisms of intron 2 of OPRK1 (kappa-opioid receptor gene) in association with opioid and cocaine dependence diagnoses in an African-American population. | Yuferov V et al. | — | 2022 | → |
| Common and distinguishing genetic factors for substance use behavior and disorder: an integrated analysis of genomic and transcriptomic studies from both human and animal studies. | Chang XW et al. | — | 2022 | → |
| Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects in brain regions associated with addiction. | Kember RL et al. | — | 2022 | → |
| Genome-wide association study in individuals of European and African ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-wide significant risk loci. | Deak JD et al. | — | 2022 | → |
| Multi-trait genome-wide association study of opioid addiction: OPRM1 and beyond. | Gaddis N et al. | — | 2022 | → |
| Novel digital approaches to the assessment of problematic opioid use. | Freda PJ et al. | — | 2022 | → |
| Strong and weak cross-inheritance of substance use disorders in a nationally representative sample. | Zhang H et al. | — | 2022 | → |
| Addiction-Associated Genetic Variants Implicate Brain Cell Type- and Region-Specific Cis-Regulatory Elements in Addiction Neurobiology. | Srinivasan C et al. | — | 2021 | → |
| A systematic review of gene-by-intervention studies of alcohol and other substance use. | Neale ZE et al. | — | 2021 | → |
| Biomarkers to predict staging and treatment response in opioid dependence: A narrative review. | Vorspan F et al. | — | 2021 | → |
| Common Polymorphisms in the <i>RGMa</i> Promoter Are Associated With Cerebrovascular Atherosclerosis Burden in Chinese Han Patients With Acute Ischemic Cerebrovascular Accident. | Hu Q et al. | — | 2021 | → |
| Different biases in meta-analyses of case-control and cohort studies: an example from genomics and precision medicine. | Palumbo SA et al. | — | 2021 | → |
| Genetics of substance use disorders: a review. | Deak JD et al. | — | 2021 | → |
| Genetics of substance use disorders in the era of big data. | Gelernter J et al. | — | 2021 | → |
| Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. | Sherva R et al. | — | 2021 | → |
| Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry. | Sanchez-Roige S et al. | — | 2021 | → |
| Genomic and Personalized Medicine Approaches for Substance Use Disorders (SUDs) Looking at Genome-Wide Association Studies. | Cozzoli D et al. | — | 2021 | → |
| The Genomics of Opioid Addiction Longitudinal Study (GOALS): study design for a prospective evaluation of genetic and non-genetic factors for development of and recovery from opioid use disorder. | Heil J et al. | — | 2021 | → |
| The Gut Microbiome and Substance Use Disorder. | Russell JT et al. | — | 2021 | → |
| The phenomics and genetics of addictive and affective comorbidity in opioid use disorder. | Freda PJ et al. | — | 2021 | → |
| Validity and utility of Hierarchical Taxonomy of Psychopathology (HiTOP): II. Externalizing superspectrum. | Krueger RF et al. | — | 2021 | → |
| Association of OPRM1 Functional Coding Variant With Opioid Use Disorder: A Genome-Wide Association Study. | Zhou H et al. | — | 2020 | → |
| Endogenous Opiates and Behavior: 2018. | Bodnar RJ | — | 2020 | → |
| Genetics and Opioids: Towards More Appropriate Prescription in Cancer Pain. | Bugada D et al. | — | 2020 | → |
| Genetic variation regulates opioid-induced respiratory depression in mice. | Bubier JA et al. | — | 2020 | → |
| Genome-wide association analysis of opioid use disorder: A novel approach using clinical data. | Song W et al. | — | 2020 | → |
| Genome-Wide Association Study of Opioid Cessation. | Cox JW et al. | — | 2020 | → |
| Genome-wide scan identifies opioid overdose risk locus close to MCOLN1. | Cheng Z et al. | — | 2020 | → |
| Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium. | Polimanti R et al. | — | 2020 | → |
| Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic. | Balyan R et al. | — | 2020 | → |
| The Genetics of Externalizing Problems. | Barr PB et al. | — | 2020 | → |
| A Contagion Model for Within-Family Transmission of Drug Abuse. | Kendler KS et al. | — | 2019 | → |
| A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans. | Cheng Z et al. | — | 2019 | → |
| A review of opioid addiction genetics. | Crist RC et al. | — | 2019 | → |
| Genomewide Gene-by-Sex Interaction Scans Identify ADGRV1 for Sex Differences in Opioid Dependent African Americans. | Yang BZ et al. | — | 2019 | → |
| Genomewide Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women. | Montalvo-Ortiz JL et al. | — | 2019 | → |
| GWAS including 82,707 subjects identifies functional coding variant in <i>OPRM1</i> gene associated with opioid use disorder | Zhou H et al. | — | 2019 | — |
| National Institute on Drug Abuse genomics consortium white paper: Coordinating efforts between human and animal addiction studies. | Cates HM et al. | — | 2019 | → |
| Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study. | Rentsch CT et al. | — | 2019 | → |
| Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients. | Muriel J et al. | — | 2019 | → |
| The Cholinergic System as a Treatment Target for Opioid Use Disorder. | Jensen KP et al. | — | 2018 | → |